Special spectacle lenses cut children's myopia progression by 71% over two years in a US trial

A child’s glasses prescription getting stronger every year is treated as an inconvenience. It is really a measurement of an eyeball getting longer, and that is a different thing.

Refractive errors happen when the shape of your eye prevents light from focusing correctly on the retina, and in myopia the specific problem is that the eyeball is too long. A long eye is stretched, and a stretched retina carries a lifelong risk that a strong prescription does not describe: detachment, myopic damage to the central retina, glaucoma.

Writing in JAMA Ophthalmology, Shen and colleagues report a randomized trial of spectacle lenses designed to slow that growth. Adjusted mean myopia progression was -0.25 D in the lenslet group and -0.90 D in the single-vision group, a 71% relative reduction, and the eyes themselves grew less.

What the lens actually does

It looks like an ordinary pair of glasses, which is most of the point.

The center of the lens is clear and corrects vision normally. The area around it carries hundreds of tiny lens elements. Spectacle lenses with highly aspherical lenslets throw light landing on the peripheral retina slightly in front of it rather than behind it.

That peripheral signal appears to be what the growing eye uses to decide whether to keep elongating. A conventional single-vision lens sharpens the central image and leaves the periphery focused behind the retina, which is thought to encourage growth. The lenslets invert that cue without disturbing what the child sees when looking straight ahead.

Two numbers, and which one matters

The trial reported both the prescription and the eye.

Adjusted mean axial elongation was 0.21 mm in the lenslet group and 0.45 mm in the single-vision group, a 53% relative reduction. Length is the outcome to watch, because the prescription is a symptom of it and because a millimeter of eyeball does not come back.

Over two years, that is about a quarter of a millimeter of growth avoided. It sounds trivial and is not: the difference between an eye that ends up 25 mm long and one that ends up 27 mm is the difference between wearing glasses and carrying a substantially raised risk of retinal disease for sixty years.

The prescription difference, 0.64 diopters over 24 months, is roughly two steps on a lens chart. Compounded across the years when eyes grow fastest, that gap widens.

Why a US trial was needed at all

These lenses have been sold in Asia for years, and the evidence behind them was Asian.

Spectacle lenses with highly aspherical lenslets are effective in Asian populations but unproven in US children, which is the specific gap this trial fills. Myopia rates, outdoor time, schooling intensity and genetic background all differ between those populations, and a treatment that works in one is a hypothesis in the other rather than a conclusion.

This is also why the trial’s design carries weight. It was double-masked, run at 9 investigational sites, and used prescriptions measured after eye drops that temporarily stop the focusing muscle from working, so a child could not unconsciously alter the reading.

What was not compromised

New optics on a child’s face raise an obvious worry: that peripheral blur is bought at the cost of clear sight.

It was not. Best-corrected visual acuity was equivalent between groups. Ocular adverse events occurred in 9 of 77 participants in the lenslet group and 12 of 82 in the single-vision group, slightly fewer with the treatment, and none were serious or lens related. Subjective symptom reports were also fewer in the treatment arm.

A safety result where the intervention arm reported marginally fewer problems than the control arm is about as reassuring as a two-year trial can be.

Where the caution belongs

159 children randomized, 135 completing, and 24 months of follow-up.

That is a real trial and a small one. Myopia progresses for a decade or more, and the question that matters is not what happens in the first two years but whether the eye that was slowed now simply catches up later, and whether the effect persists once the lenses come off. The authors are explicit that longer-term data are needed to evaluate sustained treatment efficacy.

There is also a commercial context worth naming. These findings underlie US Food and Drug Administration authorization of the study device, and trials that support a regulatory submission are usually funded by the manufacturer.

What a parent can do now

The device-specific answer belongs to an eye doctor. The general one predates this trial.

Some eye diseases can lead to vision loss without early warning signs, so it’s important to catch them as soon as possible, and children’s eyes should be checked as often as a provider recommends. A prescription that climbs noticeably each year is the signal that myopia control is worth asking about, and the options now include these lenses, specialist contact lenses and low-dose atropine drops.

The thing not to do is treat rising myopia as an administrative matter to be solved with a stronger lens each September. What this trial adds is evidence that in American children too, the growth itself can be slowed.